Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05497635
Other study ID # STSA-1002-03
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date October 14, 2022
Est. completion date April 6, 2023

Study information

Verified date April 2023
Source Staidson (Beijing) Biopharmaceuticals Co., Ltd
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is a Phase Ib, randomized, double-blind, placebo-controlled, multiple dose, dose escalation safety, tolerability,pharmacokinetic and pharmacodynamic study of STSA-1002 injection in healthy subjects. A total of 26 healthy subjects were enrolled in three dosage groups.


Recruitment information / eligibility

Status Completed
Enrollment 26
Est. completion date April 6, 2023
Est. primary completion date April 6, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria: - Healthy subjects, aged = 18 but = 45, male and female. - Weight:Male=50.0kg,Female=45kg;Body mass index: 19.0-26.0 kg/m2, inclusive. - Medical history, vital signs, physical examination, laboratory examination (including blood routine, urine routine, blood biochemistry, coagulation function test, etc.) and all tests related to the test were normal or abnormal as determined by the researcher and had no clinical significance. - Subjects (including their partners) must take effective contraceptive measures and have no birth plan or sperm or egg donation plan during the trial period and within 6 months after the end of the last administration. - Subjects are aware of the content, process and possible adverse reactions of the study and voluntarily signed the informed consent form(ICF). Exclusion Criteria: - History of tuberculosis; or combined with mixed lymphocyte culture + interferon assay results, chest imaging comprehensive evaluation of tuberculosis infection (if necessary, tuberculosis experts should be jointly evaluated). - Any clinically serious diseases such as respiratory, circulatory, digestive, urinary, blood, endocrine, neurological or mental disorder, or a history of the above diseases or any other diseases or physiological conditions that can interfere with the test results. - With any major surgical or surgical that possibly affects drug absorption, distribution, metabolism or excretion(Except appendicitis) within 2 months before screening or plan to undergo surgery during the study period. - Subjects with allergies or allergies to any components of the investigational drug and its excipients(such as allergies to two or more drugs, food, pollen), or the IgE is higher than the upper limit of normal. - Positive screening test results for human immunodeficiency virus (HIV) antibodies, syphilis-specific antibody, hepatitis B surface antigen (HBsAg) or hepatitis C antibody (HCVAb). - Subjects with abnormal blood white blood cell count and absolute neutrophil count during the screening period with clinical significance; or hemoglobin: male <120g/L or female <110g/L. - Drug abuse within 1 year before screening [such as morphine, ketamine (K powder), THC (marijuana), methamphetamine (ice), MDMA (ecstasy) ), cocaine, etc.]; or positive urine screening for drug abuse. - Subjects who have taken drugs that may affect immune function within 6 months before screening, have received any monoclonal antibody or biological agent for treatment (for any illness) within the previous 3 months, and have taken prescription drugs,non-prescription drugs,chinese herbal medicine within 14 days before screening. - Alcoholism within 6 months before screening (drinking more than 14 units of alcohol per week: 1 unit = 285mL of beer, or 25mL of spirits, or 100mL of wine) or unable to stop consuming any alcoholic products after enrollment until the entire study period or a positive alcohol breath test result. - Subjects who smoking (more than 5 cigarettes per day on average) within 3 months before screening or who could not stop using any tobacco products until the whole study period after enrollment. - Subjects who drink too much (more than 8 cups a day, 1 cup = 200 mL) of tea, coffee and other beverages rich in xanthine within 3 months before screening, or food or beverages that affect drug absorption, distribution, metabolism, and excretion. - Donation of blood or lost more than 400ml within 3 months before the first investigational product administration or plan to donate blood or blood components during the study period or within 3 months after the end of the study, or have a history of blood transfusion within 4 weeks before the first drug use of the study. - Subjects who participated in any unmarked drug, vaccine or medical device clinical trial within 3 months before screening and applied the drug, vaccine or medical device in the trial. - Vaccination within 14 days before the first dose or ready to be vaccinated during the study period to 2 months after the end of the study. - Subjects who have used long-acting estrogen or progestogen injections or implants within 6 months before the study or those who have used short-acting contraceptives within 4 weeks before the study. - Female subjects who have had unprotected sex within 14 days prior to screening. - Blood ß-HCG test positive or above the upper limit of the normal range (Female subjects). - Pregnant or lactating. - Any food or drink rich in xanthine (such as coffee, strong tea, chocolate, etc.) or food or drink that affects drug absorption, distribution, metabolism, and excretion within 48 hours before administration. - Unable to follow a unified diet (such as special requirements for diet, intolerance to standard meals, etc.). - Intolerance to venipuncturing blood collection, transfusion, or a history of blood and needle sickness. - Other circumstances in which the researcher considers it inappropriate to participate in the study.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
STSA-1002 Injection
Intravenous injection
Placebo
Intravenous injection

Locations

Country Name City State
China Beijing Shijitan Hospital, Capital Medical University Beijing Beijing
China The Second Affiliated Hospital Of Xingtai Medical College Xingtai Hebei

Sponsors (1)

Lead Sponsor Collaborator
Staidson (Beijing) Biopharmaceuticals Co., Ltd

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of Adverse Events?Clinically Significant Laboratory Abnormalities?Clinically Significant Electrocardiogram?Vital Signs And Physical Examination Abnormalities. To evaluate the safety and tolerability of multiple intravenous administration of STSA-1002 in healthy adult subjects. Up to Study Day 56
Primary Maximum plasma concentration (Cmax) To evaluate the single dose pharmacokinetics (PK) characteristics of STSA-1002 in healthy adult subjects From Day 0 to Day 56
Primary Area under the plasma concentration-time curve from time 0 to the collection time point t of the last measurable concentration (AUC0-t) To evaluate the single dose pharmacokinetics (PK) characteristics of STSA-1002 in healthy adult subjects From Day 0 to Day 56
Primary Area under the plasma concentration-time curve from time 0 to infinity (AUC0-8) To evaluate the single dose pharmacokinetics (PK) characteristics of STSA-1002 in healthy adult subjects From Day 0 to Day 56
Primary Time of maximum concentration (Tmax) To evaluate the single dose pharmacokinetics (PK) characteristics of STSA-1002 in healthy adult subjects From Day 0 to Day 56
Primary Elimination half-life (t1/2) To evaluate the single dose pharmacokinetics (PK) characteristics of STSA-1002 in healthy adult subjects From Day 0 to Day 56
Primary Mean residence time (MRT) To evaluate the single dose pharmacokinetics (PK) characteristics of STSA-1002 in healthy adult subjects From Day 0 to Day 56
Primary Clearance (CL) To evaluate the single dose pharmacokinetics (PK) characteristics of STSA-1002 in healthy adult subjects From Day 0 to Day 56
Primary Apparent volume of distribution (Vz) To evaluate the single dose pharmacokinetics (PK) characteristics of STSA-1002 in healthy adult subjects From Day 0 to Day 56
Primary Maximum Concentration of the Analyte in Plasma at steady state(Cmax, ss) To evaluate the multidose PK characteristics of STSA-1002 in healthy adult subjects From Day 0 to Day 56
Primary Minimum Measured Concentration of the Analyte in Plasma at Steady State(Cmin, ss) To evaluate the multidose PK characteristics of STSA-1002 in healthy adult subjects From Day 0 to Day 56
Primary Time-averaged concentration at steady state(Cav, ss) To evaluate the multidose PK characteristics of STSA-1002 in healthy adult subjects From Day 0 to Day 56
Primary Area under the concentration curve from time 0 extrapolate to infinite time(AUCinf,ss) To evaluate the multidose PK characteristics of STSA-1002 in healthy adult subjects From Day 0 to Day 56
Primary Degree of fluctuation(DF) To evaluate the multidose PK characteristics of STSA-1002 in healthy adult subjects From Day 0 to Day 56
Primary Accumulation factor To evaluate the multidose PK characteristics of STSA-1002 in healthy adult subjects From Day 0 to Day 56
Secondary Change from baseline in concentration of free C5a and anti-drug antibody To evaluate the pharmacodynamics (PD) characteristics and immunogenicity of STSA-1002 in healthy subjects From Day 0 to Day 56
Secondary Change from baseline in concentration of Myeloperoxidase(MPO)?Neutrophil elastase(NE)?Proteinase3(PR3)? C-X-C chemokine receptor 1(CXCR1) To evaluate the effect of STSA-1002 on MPO?NE?PR3?CXCR1 From Day 0 to Day 56
See also
  Status Clinical Trial Phase
Active, not recruiting NCT02664883 - Myeloid Derived Suppressor Cells Clinical Assay in Finding Kidney Cancer
Completed NCT05611281 - GS3-007a Oral Solution in Healthy Subjects Phase 1
Completed NCT03457480 - Text Messages in Preventing Tobacco Use in Young Adults N/A
Completed NCT05358756 - A Study of Bioavailability and Food Effect of SACT-1 and Edurant® Tablets in Healthy Adult Volunteers Phase 1
Completed NCT06037395 - Phase I Study to Compare the Pharmacokinetics, Pharmacodynamics, and Safety Between CT-P41 and US-licensed Prolia in Healthy Male Subjects Phase 1
Active, not recruiting NCT04032106 - HPV Vaccine Intervention for Young Sexual Minority Men N/A
Completed NCT04062955 - Effects of Alternative Healthy Eating Index-Based Diet on Inflammatory Markers and Breast Density in Healthy Participants N/A
Recruiting NCT03897270 - Photoacoustic Imaging of the Breast in Patients With Breast Cancer and Healthy Subjects N/A
Completed NCT01846520 - Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung Cancers N/A
Completed NCT02960100 - mHealth Intervention in Increasing HPV Vaccinations in College Students N/A
Completed NCT03698318 - Pharmacokinetics Assessing Bioavailability of Gingerols and Shogaols of Five Ginger Extracts N/A
Active, not recruiting NCT03303846 - Combined Breast MRI and Biomarker Strategies in Identifying High-risk Breast Cancer Patients N/A
Terminated NCT05559125 - A Study of STSA-1002 Combined With STSA-1005 in Healthy Subjects Phase 1
Completed NCT03584100 - Effect of Pneumatic Tourniquet on Arm Swelling After Lymph Node Removal N/A
Recruiting NCT05117385 - The Effect of the Consumption of 4 Botanical Extracts on Immunity in Healthy Adults (B-4-Immune) N/A
Active, not recruiting NCT05660720 - Evaluate the Effect of Orelabrutinib on Cardiac Repolarization in Healthy Subjects Phase 1
Recruiting NCT03188848 - Dose Escalating Study of BPI-3016 in Healthy Subjects Phase 1
Completed NCT01908920 - Osteopathic Manipulative Treatment Effects on High Frequency Parameters in Healthy Subjects N/A
Active, not recruiting NCT03491176 - Magnetic Resonance (MR) Imaging & Blood Biomarkers for Head and Neck Cancer N/A
Completed NCT03963323 - Glucosamine and Chondroitin in Gut in Preventing People From Inflammation Phase 1